The Hemophilia A market growth is driven by factors like increase in the prevalence of Hemophilia A, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Hemophilia A market report also offers comprehensive insights into the Hemophilia A market size, share, Hemophilia A epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Hemophilia A market size growth forward.
Some of the key highlights from the Hemophilia A Market Insights Report:
Strategise your business goals by understanding market dynamics @ Hemophilia A Market Landscape
Hemophilia A Overview
Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. People with hemophilia A will bleed more than normal after an injury, surgery, or dental procedure. This disorder can be severe, moderate, or mild. In severe cases, heavy bleeding occurs after minor injury or even when there is no injury (spontaneous bleeding). Bleeding into the joints, muscles, brain, or organs can cause pain and other serious complications. In milder forms, there is no spontaneous bleeding, and the disorder might only be diagnosed after a surgery or serious injury. Hemophilia A is caused by having low levels of a protein called factor VIII. Factor VIII is needed to form blood clots. The disorder is inherited in an X-linked recessive manner and is caused by changes (mutations) in the F8 gene.
Hemophilia A Symptoms
The symptoms of hemophilia A and the age symptoms appear vary depending on the amount of factor VIII a person’s body makes. Infants with the severe form may bleed abnormally from their mouth and develop ‘goose eggs’ on their heads (collections of blood under the scalp). Other symptoms of the severe form include bleeding without any known cause (spontaneous bleeding) into the muscles, joints, and organs. Children with the moderate form may bruise easily and bleed too much after minor injuries, dental work, or surgery. People with the mild form of hemophilia A may not be diagnosed until they bleed more than normal after a major injury or surgery. With the mild form, there are no episodes of spontaneous bleeds.
Hemophilia A Diagnosis
The diagnosis of hemophilia A is made through the clinical symptoms and confirmed by laboratory testing. Blood tests are done to measure the time it takes the blood to clot and the amount of clotting factors found in the blood. Genetic testing can also help determine the exact change in the F8 gene and can be helpful for identifying other family members at risk for hemophilia A.
Hemophilia A Treatment
There is no cure for hemophilia A, but current treatments can prevent many of the symptoms of hemophilia A. Treatment may include medications and replacing the missing clotting factor (replacement therapy). This type of replacement therapy is done by slowly injecting or dripping concentrated factor VIII into a vein (intravenous infusion). The type and frequency of treatment often depends on the severity of the disorder in each person.
Do you know the treatment paradigms for different countries? Download our Hemophilia A Market Sample Report
Recent Breakthroughs in the Hemophilia A Market:
US FDA approves BioMarin’s gene therapy for hemophilia A: The U.S. Food and Drug Administration on Thursday approved BioMarin Pharmaceutical’s (BMRN.O) gene therapy for severe hemophilia A, the company said, giving patients with the inherited bleeding disorder an alternative to regular injections of missing blood proteins. It priced the one-time therapy, Roctavian, at $2.9 million. Pivotal trial results showed that Roctavian reduced bleeding events, but its durability is not known, and the company said it would include a warranty to health insurers.
Hemophilia A Epidemiology Segmentation
DelveInsight’s Hemophilia A market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Hemophilia A historical patient pools and forecasted Hemophilia A patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Hemophilia A Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Visit for more @ Hemophilia A Epidemiological Insights
Hemophilia A Treatment Market
The Hemophilia A market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hemophilia A market trends by analyzing the impact of current Hemophilia A therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Hemophilia A market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hemophilia A market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Hemophilia A market in 7MM is expected to witness a major change in the study period 2019-2032.
Hemophilia A Emerging Drugs
AGN-193408: Allergan
Allergan is conducting a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-group (Cohort 2) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension. It is an implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix.
OCTA101: Octapharma
Octapharma is evaluating OCTA101 (a human-cl rhFVIII and recombinant human von Willebrand Factor fragment dimer) under a Phase 1/2 study, which will be a dose escalation study in adults in 5 cohorts, with the main purpose to assess the safety of subcutaneous injection of OCTA101 (in previously treated adult patients with severe hemophilia A. The study also aims to assess the pharmacokinetics (PK) characteristics, dose proportionality, and subcutaneous bioavailability of OCTA101 compared with intravenous administration of Nuwiq (Human-cl rh FVIII), in order to define the prophylactic treatment (dose and injection interval) that would result in protective trough levels of FVIII:C for future Phase 3 studies. By Data Monitoring Committee recommendation, patients enrolled in cohorts 1, 2 and 3 will proceed to 3-month prophylactic treatment to receive daily dosing of OCTA101 for 3 months.
Valoctocogene roxaparvovec: BioMarin Pharmaceuticals
Valoctocogene roxaparvovec, is an investigational gene therapy in clinical trials for the treatment of Hemophilia A and has not been determined to be safe or effective. Valoctocogene roxaparvovec is administered as a single infusion. The ongoing clinical trials will determine if the new gene will enable the body to produce factor VIII. Following infusion, clinical trial subjects are being evaluated to determine the safety profile, changes in Factor VIII activity levels, changes in factor replacement usage, changes in reported bleeds requiring factor replacement, and quality of life measures, among other endpoints.
Hemophilia A Key Companies
For more information, visit Hemophilia A Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Hemophilia A Market Report:
Key Questions Answered in the Hemophilia A Market Report 2032:
Table of Contents:
1 Hemophilia A Market Key Comprehensive Insights
2 Hemophilia A Market Report Introduction
3 Competitive Intelligence Analysis for Hemophilia A
4 Hemophilia A Market Analysis Overview at a Glance
5 Executive Summary of Hemophilia A
6 Hemophilia A Epidemiology and Market Methodology
7 Hemophilia A Epidemiology and Patient Population
8 Hemophilia A Patient Journey
9 Hemophilia A Treatment Algorithm, Hemophilia A Current Treatment, and Medical Practices
10 Key Endpoints in Hemophilia A Clinical Trials
11 Hemophilia A Marketed Therapies
12 Hemophilia A Emerging Therapies
13 Hemophilia A: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Hemophilia A
16 Hemophilia A Market Key Opinion Leaders Reviews
18 Hemophilia A Market Drivers
19 Hemophilia A Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Hemophilia A Epidemiology 2032
DelveInsight’s “Hemophilia A – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Hemophilia A epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Hemophilia A Pipeline 2023
“Hemophilia A Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hemophilia A market. A detailed picture of the Hemophilia A pipeline landscape is provided, which includes the disease overview and Hemophilia A treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +91-9650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
